CClinicalTrials.gg
Sign In
Status unknownNCT02286648Updated Nov 10, 2014

Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars

A Phase 4 interventional study of Formocresol and Mineral Trioxide Aggregate in Pulpitis, Dental Pulp Disease and Tooth Diseases, sponsored by Mashhad University of Medical Sciences. Status unknown at 2 sites in Iran, Islamic Republic of. Open to participants aged 4 Years to 7 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-10.

Sponsored by Mashhad University of Medical Sciences · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2014), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
4 Years to 7 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the clinical and radiographic success rate of Miniature pulpotomy with Mineral Trioxide Aggregate (MTA) in primary molars.

02

Conditions studied

  • Pulpitis
  • Dental Pulp Disease
  • Tooth Diseases

Keywords

  • clinical signs
  • child
  • pulpotomy
03

In context

Pulpitis

302 studies on the registry are indexed under Pulpitis; 67 are open to participants now.

This study's planned enrollment of 50 is below the median of 62 across 275 interventional studies indexed under Pulpitis.

Browse Pulpitis studies →

Lead sponsor

Mashhad University of Medical Sciences is the lead sponsor of 90 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • healthy people(without any systemic disease)

  • teeth :

    • no clinical or radiographic evidence of pulp degeneration
    • the possibility of proper restoration of the teeth

Exclusion criteria

Exclusion Criteria:

  • teeth :

    • excessive bleeding from the exposure site
    • internal root resorption
    • interradicular and/or periapical bone destruction
    • swelling or sinus tract
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Mineral Trioxide Aggregate

    pulpotomy with MTA

    Drug: Mineral Trioxide Aggregate

  • Active comparator
    Formocresol

    pulpotomy with FC

    Drug: Formocresol

Interventions

  • DrugFormocresol

    pulpotomy with formocresol

  • DrugMineral Trioxide Aggregate

    pulpotomy with MTA

06

What researchers measure

Primary outcomes

  1. successful outcome of treatment as indicated by clinical signs defined with observation and check list

    success or failure of treatment defined with observation and check list

    Time frame: up to 12 months

Secondary outcomes

  1. successful outcome of treatment as indicated by radiographic signs defined with observation and check list

    success or failure of treatment defined with observation and check list

    Time frame: up to 12 months

07

Study locations

2 of 2 sites recruiting
  • Mashhad University of Medical Siences
    Mashhad, Khorasan Razavi 9185769516, Iran, Islamic Republic of
    • Hossein Nematollahi, associate of professor · Contact
    • Homa Noorollahian, associate of professor · Contact
    • Hossein Nematollahi, associate of professor · Principal investigator
    Recruiting
  • Mashhad University of Medical Siences
    Mashhad, Khorasan Razavi 9185769516, Iran, Islamic Republic of
    • Hossein Nematollahi, associate of professor · Contact
    • Homa Noorollahian, associate of professor · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02286648
Lead sponsor
Mashhad University of Medical Sciences
Responsible party
Hossein Nematollahi (principal investigator, Mashhad University of Medical Sciences) — Principal investigator
First posted
Nov 10, 2014
Start date
Feb 2014
Primary completion
Jul 2015 (estimated)
Last update
Nov 10, 2014

Study contacts

Hossein Nematollahi, associate prof.
Contact
nematollahih@mums.ac.ir
+989151141688
Homa Noorollahian, Associate prof.
Contact
noorollahianh@mums.ac.ir
+989155577184

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulpitis→

Other studies from this sponsor

Mashhad University of Medical Sciences

Start the discussion